KSB Q1 FY27: Consolidated PAT falls 19% YoY to ₹57 Cr on valves margin collapse
PAT -18.75% YoY · revenue +3.6% · margins compressing
₹690.7 Cr
+3.6% YoY
₹57.2 Cr
-18.75% YoY
8.22%
-2.2pp YoY
₹3.29
KSB's consolidated PAT for the quarter ended 30 June 2026 came in at ₹57.2 Cr, down 18.8% YoY from ₹70.4 Cr, even as revenue from operations grew a modest 3.6% YoY to ₹690.7 Cr (₹666.7 Cr). Sequentially the print looks much stronger — PAT is up 43.7% QoQ and revenue up 14.9% QoQ off a seasonally soft March quarter — but per the YoY-primary read this is a weak quarter: profit growth trailed revenue growth by a wide margin, and both operating margin (11.8% vs 13.7% YoY) and net margin (8.2% vs 10.4% YoY) compressed. No analyst consensus estimates for this specific quarter were found in a web search, so the print cannot be benchmarked against Street numbers; vsStreet is marked unknown rather than guessed.
Q1 FY-2027 vs prior quarters
The margin compression is not evenly spread across the business. Segment data shows the Pumps business held up reasonably well — revenue of ₹581.0 Cr (+5.4% YoY) and segment profit of ₹65.0 Cr, roughly flat on ₹64.0 Cr YoY (margin ~11.2% vs 11.6%). The real damage is in Valves: revenue fell 4.8% YoY to ₹110.7 Cr and segment profit collapsed to ₹4.5 Cr from ₹17.8 Cr a year ago — a margin compression from 15.3% to 4.1%. A ₹5.0 Cr YoY drop in 'other unallocable income' (₹2.4 Cr vs ₹7.4 Cr) and a rise in finance costs (₹1.4 Cr vs ₹0.7 Cr) added further drag; together these items account for almost the entire ₹17.5 Cr YoY decline in consolidated PBT.
The stock went into the print at ₹872.6, down 6.6% over the past month of trading.
What the summary numbers don't show
No exceptional items this quarter (unlike FY2025's ₹25.5 Cr labour-code charge), so the YoY profit decline is fully operational, not one-off-driven
Management guides for 15-20% revenue growth in the pump segment for CY2026, driven by a strong order book and the commencement of nuclear project execution. The company aims to maintain EBITDA margins around 13-14% by balancing project business with high-margin aftermarket and export sales, though commodity price volat
— This quarter: missed
Against management's own guidance from the last concall — 15-20% pump-segment revenue growth for CY2026 and EBITDA margins sustained around 13-14% — this quarter falls short on both counts: pump growth of 5.4% YoY is well below the guided band, and consolidated OPM of 11.8% sits below the 13-14% target, consistent with management's flagged commodity-cost watchpoint. The quarter's other developments — the switch of statutory auditor from Price Waterhouse to B S R & Co. LLP, confirmed via an AGM addendum and a revised (unchanged-numbers) results intimation in April — are procedural and don't bear on the operating numbers. No company press release commentary was available at the time of this analysis, so management's own framing of the quarter could not be cross-checked against the figures.
W1
Valves segment margin recovery — fell to 4.1% (₹4.5 Cr) from 15.3% (₹17.8 Cr) YoY; watch for a bounce toward historical mid-teens levels next quarter
W2
Pump-segment revenue growth of 5.4% YoY trails management's guided 15-20% CY2026 band — watch whether nuclear-project execution accelerates in H2
W3
Consolidated EBITDA margin at 11.8% remains below management's guided 13-14% range — watch for commodity-cost/mix normalization
Figures converted from INR Million to INR Crore (÷10). Consolidated PBT (₹74.7 Cr) = Total Income − Total Expenses (₹70.5 Cr) + ₹4.2 Cr share of associate (KSB MIL Controls) profit — the associate line, not a calc error. No exceptional items in this or the year-ago quarter; the ₹25.5 Cr 'impact of new labour codes' exceptional item sits only in the FY2025 annual column.
Weak Q1 masks long-term nuclear/infra tailwinds; near-term margin pressure
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Achieved 17% CAGR revenue and 22% CAGR PAT historically. Q1 miss is material—both revenue and profit below prior guidance; company defaulting to H2 recovery and long-term narrative.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
KSB delivered soft Q1 (3.6% revenue, -18.8% PAT) blamed on geopolitical crisis, supply-chain stress, and commodity inflation in fixed-price contracts. Management is defending near-term through cost control and hoping H2 recovery, but near-term visibility is weak and nuclear project execution is delayed. Long-term nuclear/data-centre tailwinds are real, but structural. Awaiting execution risk: GHAVP testing resolution, export clearance normalization, and competitor pressure on nuclear.
₹690.7 Cr
Revenue · +3.6% YoY₹57.2 Cr
Reported PAT · −18.8% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Geopolitical crisis, supply chain issues temporary drivers of H1 weakness
Revenue +3.6% YoY despite claims of growth opportunities; OPM 11.8% vs 13-14% target
Partially Supported
Strong order intake growth and order book ₹27,445 Cr in June 2026
Order intake H1 FY27 ₹15,307 Cr (excluding nuclear) at 14% CAGR; reported but actual growth rate not disclosed
Unverified
Expected much better performance in H2 with export recovery
As of call (August), exports have not yet recovered; only inquiries and projects started, results awaited
MISS
Valves margin decline temporary; will return to double-digit
H1 valves margin fell to single-digit from mid-teens historically; company concedes need for sales recovery to normalize
OVERSTATED
Earnings quality
What changed since the last call
Export headwinds & supply-chain stress materialized
DowngradeH1 exports faced geopolitical delays (war, tariffs); supply-chain issues cut production. 80-85% resolved now but full recovery delayed to H2. Inventory backlog still being diluted.
Solar business derailed; KUSUM 2.0 delayed
DowngradeSolar revenue ₹50-60Cr (H1) vs expectations; only 5-7% of order book. Prior guidance implied stronger ramp. Scheme delay pushed recovery to Q3/Q4.
Valves margin collapse—not temporary
DowngradeValves fell to single-digit margins vs mid-teens historically. Company attributes to commodity costs & export mix but hasn't passed full costs to customers; mitigation vague.
Nuclear testing delays; GHAVP stalled
DowngradeGHAVP testing hit issues at NPCIL test-bed (outside KSB's control). Testing now expected Sep 2026 onward. Revenue recognition pushed back further; execution risk remains on new tenders.
Full-year growth guidance softened
NeutralPrior calls guided 15-20% revenue growth & 13-14% EBITDA. Now aiming for 'double-digit' (10%+) and 15-17% 'average,' more hedged. No explicit cut but tone is cautious.
The Q&A
Analysts pressed hard on margin compression (valves, foundry costs), project business slowdown, nuclear execution delays, and capex intensity. Management defended with temporary factors (geopolitical, supply chain) and H2 recovery hopes, but offered few quantitative commitments. Q&A showed skepticism on near-term visibility; management held firm on long-term positioning.
Macro growth & sector outlook — Saurabh Mehta, East Lane Capital
AnsweredEnergy (nuclear, conventional, renewable) leading; infrastructure (water, wastewater, airports, metros) secondary. Thermal 50GW under construction offers growth. Localization drives incremental opportunities.
Nuclear execution & competition — Saurabh Mehta, East Lane Capital
PartialKudankulam safety package on track; GHAVP testing stalled on NPCIL test-bed issues, resuming Sep. New tender 'next few months' for ~8 reactors. KSB is approved supplier; NPCIL decides competition.
H1 subdued performance — Shubham Murade, ICICI Securities
AnsweredGeopolitical war halted export deliveries; ready pumps stuck. Supply chain issues resolved 80-85%. Data Centre growing globally; India focusing on liquid cooling, OEM orders emerging.
Nuclear pump execution cycle — Unidentified Analyst
AnsweredLocalization = parts previously imported now Made in India (mechanical seals, rotor parts, castings, Hurth gears). Design/tech from parent. Kudankulam redesigned in India due to geopolitical shifts.
Nuclear pump execution cycle & timeline — Unidentified Analyst
AnsweredStandard cycle 24-36 months; deliveries to NPCIL ~48 months from order. Primary coolant pump ordered early (with steam generator). Testing dependent on NPCIL test-bed.
Valves margin collapse — Unidentified Analyst
PartialCommodity prices, product mix, exports down, sales down. Combination of factors. Temporary; expect double-digit margin once sales recover and situation normalizes.
Solar business & KUSUM 2.0 — Unidentified Analyst
AnsweredSolar H1 ₹50-60Cr (much below expectations) due to KUSUM 2.0 delayed to Q4. Got Maharashtra tender orders; expect pickup in Q3. Only 5-7% of order book vs 10-12% target.
Order intake growth slowdown — Mohit Surana, Monarch Networth Capital
AnsweredStandard business growing but takes time (new markets: fire-fighting, marine, mining). Project market (oil & gas, petrochemical) slowed. Water/wastewater re-entering after years; product development underway. Supercritical thermal breakthrough (boiler circulation pump localized). Selective approach.
Full-year growth guidance — Mohit Surana, Monarch Networth Capital
PartialGoal is double-digit growth. Nuclear testing delay a risk but low. Average 15-17% reasonable; 20% possible but peaky and unreliable. 10-15% volume, 15% value a good base.
Gas/commodity cost pass-through — Mohit Surana, Monarch Networth Capital
AnsweredFoundries given 12-15% price increases; company passing single-digit to customers (phased). Margins under pressure 3-6 months lag. 85-90% supply stability now; cost agreements settled.
BP&CL integration & trajectory — Unidentified Analyst
PartialPSU business requires proven track record (PTR), public tendering (GeM portal). Building inroads to ONGC, Oil India. Reciprocating pump EIL approval being pursued. Medium-term target ₹40-50Cr annually. Takes time in Indian PSU context.
SupremeServ aftermarket growth — Unidentified Analyst
AnsweredDedicated Chinchwad facility; warehouse for spare parts giving steady monthly revenue. Boiler circulation pump refurbishment orders started (new). Descaling pump localization orders (Japanese suppliers being replaced). Growing 15% p.a. Target 25-30% revenue share (excluding agri, lower is ok vs global 35%).
Export performance & order book — Unidentified Analyst
PartialCurrent order book ~15% of sales (target 20%). Potential high but geopolitical disruptions (US tariffs, Middle East war) unpredictable. US boiler feed pumps for gas power plants, Middle East API leader, desalination market potential.
Receivables days trend — Unidentified Analyst
AnsweredSolar business caused spike (state government payment lags, fund availability). Expect good momentum in H2 but won't improve dramatically (average metric). Documentation/fund availability dependent.
JJM water scheme & BP&CL track — Unidentified Analyst
PartialJJM: positivity but still struggling on past projects; not yet visible. BP&CL: on track; PSU business takes time; building step-by-step. Targeting ₹40-50Cr annually.
Engineered pumps & project decline — Unidentified Analyst
PartialFirst half slow on project pumps; many projects waiting to finalize (temporary). Inventory mainly export orders awaiting clearance, FGD business closure, solar slowdown. Not nuclear. Will be diluted.
HANA implementation risk — Unidentified Analyst
PartialS/4HANA mandatory; will improve internal efficiency, remove workarounds. Lift-and-shift phase then innovation. OpEx impact next year (shared with group). Not quantified; board to approve.
Guidance
Double-digit growth for full year; 15-17% average reasonable; 20% possible but peaky
MediumAiming for but hedged due to nuclear delays, export recovery uncertainty, and project finalization lag. H2 expected much better. Risks: GHAVP testing resolution, new tender timing.
EBITDA margins target 13-14%; maintained
LowH1 OPM 11.8% vs target. Company cites temporary factors (commodity inflation, fixed contracts). Expects mitigation through higher sales volume and cost reduction. Timeline not specified.
Annual CapEx ₹80-100-120Cr (sustenance + growth); nuclear capacity +20% at Shirwal
HighMix of machine replacement, nuclear/product development, office upgrades for employee engagement. Annual run-rate committed.
Risks the call surfaced
Nuclear execution
HighGHAVP primary coolant pump testing stalled due to NPCIL test-bed issues. Testing delayed to September. Revenue recognition pushed back. New tender timing uncertain.
Margin compression
HighFixed-price project contracts under pressure from foundry cost inflation (12-15% hikes). Company only passing single-digit increases to customers in standard business. Gross margins compressed; OpEx also hit.
Export disruption
HighH1 exports suffered from geopolitical crisis (war). Ready-for-delivery pumps stuck. Supply-chain issues (85-90% resolved) still impacting delivery. Inventory backlog ₹15-20Cr being diluted. Export order book recovery timing uncertain.
Valves margin collapse
MediumValves division margin fell to single-digit (from mid-teens historically) due to commodity prices, product mix, and export volume decline. Company attributes to temporary factors but timing for recovery vague.
Solar business slowdown
MediumKUSUM 2.0 scheme delayed to Q4; H1 solar revenue ₹50-60Cr (5-7% of order book) vs expectations of 10-12% target share. Product development time required for new segments. Receivables days impacted by state government payment lags.
Nuclear competition
MediumAnalyst question on Kirloskar Brothers and Flowserve entering primary coolant pump space. NPCIL approval not exclusive; new tenders may introduce competition. KSB has 47 years experience and learning curve advantage but not guaranteed monopoly.
Management
Score 6/10. Transparent on headwinds (geopolitical, supply-chain, commodity inflation) but overly reliant on 'temporary' narrative. Specific numbers on cost recovery and margin timelines sparse. Open Q&A but deflects on quantitative guidance. Historical 17% CAGR revenue, 22% CAGR PAT but Q1 missed guidance badly (3.6% revenue, -18.8% PAT). Nuclear project delays show execution dependency on external partners. Supply-chain stabilization claims partially validated (80-85% done).
1 · August 2026 (now)
GHAVP nuclear pump testing expected to resume after test-bed issue resolution
2 · September 2026
GHAVP 500-hour pump test cycle begins; 2-3 month duration to validation & dispatch
3 · Next few months
New nuclear tender for 8 reactors (Mahi Banswara, Ashvini JV) expected; KSB is approved supplier
Awaiting execution risk: GHAVP testing resolution, export clearance normalization, and competitor pressure on nuclear.
Margin Squeeze Masks Nuclear Opportunity—Q1 Misses Revenue and Profit Guidance
Revenue guidance was missed by 75% (3.6% actual vs 15–20% prior) and profit collapsed 18.8% despite top-line growth. The call reveals a margin squeeze from fixed-price contracts under commodity inflation, plus delays in the nuclear tailwind that underpins the long-term bull case.
₹690.7 Cr
+3.6% YoY (vs 15–20% prior guidance)
₹57.2 Cr
−18.8% YoY (vs growth expected)
11.8%
vs 13–14% target
₹27,445 Cr
June 2026; nuclear ₹1,235 Cr
KSB's Q1 result lands softly on a foundational promise: revenue is up, but profit is down. The 3.6% revenue growth rings hollow against the 15–20% prior guidance—a 75% miss on the headline. More telling, net profit fell 18.8% despite the top line, a margin squeeze that management pinned on temporary factors (geopolitical crisis, supply-chain stress, commodity inflation) but the call transcript reveals is structural in places.
Where the profit went: A margin collapse, not a cyclical hiccup
Operating profit margin contracted to 11.8% from the 13–14% target. Two segments are bleeding: valves fell to single-digit margins from mid-teens historically, and fixed-price project contracts are squeezed by foundry cost inflation (12–15% hikes) that customers won't absorb in full. The company is passing only single-digit price increases through, creating a multi-quarter margin lag.
Geopolitical crisis & supply-chain stress are temporary H1 headwinds
Supply-chain 80–85% resolved; exports still awaiting clearances (not yet recovered). Inventory buildup (export orders, FGD closure, solar) still being diluted.
Partially supported
Strong order intake growth and ₹27,445 Cr order book
Order intake H1 ₹15,307 Cr (excl. nuclear) at 14% CAGR confirmed; order book confirmed. Actual YoY growth rate not disclosed.
Unverified
Expected much better performance in H2 with export recovery
As of call date (August 2026), exports have not yet recovered; only inquiries and projects initiated. Results awaited.
Contradicted
Valves margin collapse is temporary; will return to double-digit
H1 valves margin fell to single-digit from mid-teens. No timeline given; management cites need for sales recovery to normalize.
Overstated
What changed on this call: Four downgrades, one hedged recovery
Export headwinds materialized (geopolitical delays); recovery pushed to H2 but unconfirmed
Solar business missed badly (₹50–60 Cr H1 vs plan); KUSUM 2.0 delayed to Q4
Valves margin collapse is structural (commodity cost pass-through blocked); no timeline for recovery
Nuclear GHAVP testing stalled on NPCIL test-bed issues; resuming Sep 2026 (external dependency)
Revenue guidance softened implicitly: from 15–20% to 'double-digit' (10%+) and 'average 15–17%' going forward. Management is hedging on nuclear delays, export recovery uncertainty, and project finalization lag. H2 is now the recovery bet, not a certainty.
The bull-bear ledger
Nuclear tailwind is structural: 100GW target by 2047; ₹1,235 Cr order book in hand
17% revenue CAGR and 22% PAT CAGR history; proven execution capability
Data-centre liquid-cooling opportunity emerging; international OEM orders initiating
Q1 revenue growth 3.6% vs 15–20% guidance is a material miss
PAT declined 18.8% despite revenue growth; margin squeeze is real and material
Fixed-price contract inflation is structural, not temporary; recovery path unclear
Valves segment fell to single-digit margin; management offers no specifics on recovery timeline
Nuclear execution dependent on NPCIL test-bed (outside KSB's control); tender timing unconfirmed
Geopolitical disruptions (tariffs, war) unpredictable; export recovery timing guessed, not known
How the street is positioned
The market's skepticism has held and deepened. The stock fell 7.59% on day 1 post-result and the move worsened to −8.48% by day 3, settling −5.26% by day 5—a negative reaction that did not fade. At ₹796.45, the stock is now −22.55% from its all-time high and trading below its 20-day (₹809.06), 50-day (₹872.47), and 200-day (₹807.98) moving averages. Technically, it is in a confirmed downtrend.
Foreign institutional investors have trimmed: FII ownership fell to 4.10% from 4.66% in the prior quarter (−56 basis points). Domestic institutions held steady at 11.77% (up 13 bps), and promoters remain locked at 69.80%. The divergence (FII exiting, DII holding) suggests hesitation on the recovery narrative among the most price-sensitive buyers.
Risks, ranked by holder concern
Fixed-price contract margin squeeze is structural, not temporary
HighFoundry costs up 12–15%; KSB passing only single-digit increases to customers due to fixed-price contract terms. This is a multi-quarter margin headwind, not one-time. Mitigation (cost control, volume leverage) remains vague.
Nuclear GHAVP testing delayed; execution dependent on NPCIL test-bed (external)
HighGHAVP testing hit issues at NPCIL test-bed, resuming Sep 2026. Revenue recognition pushed back. New tender timing ('next few months') unconfirmed. KSB has no control over external test-bed or NPCIL procurement pace.
Valves margin collapsed to single-digit; no recovery timeline disclosed
HighValves division dropped from mid-teens to single-digit margins due to commodity costs and export weakness. Management expects recovery 'once sales normalize' with no quantitative target or timeline. 19% of order intake at risk.
Export recovery timing is guessed, not known; geopolitical disruptions ongoing
MediumExports face tariff and war delays. Supply-chain stabilization (80–85% done) cited as proof, but actual order clearance and delivery timing remain uncertain. Further geopolitical deterioration could push recovery beyond H2.
Solar business slowdown due to KUSUM 2.0 delay; execution risk on government timelines
MediumSolar revenue ₹50–60 Cr H1 (5–7% of order book) vs 10–12% target, entirely due to KUSUM 2.0 delay to Q4. Scheme delay beyond Q4 or government funding constraints could derail solar ramp. State government payment lags also hit receivables.
Guidance softened; no quantitative commitment to H2 recovery
MediumFull-year guidance downgraded from 15–20% to 'double-digit' and 'average 15–17%'. Management relies on H2 recovery narrative but disclosed few internal levers (cost actions, pricing milestones) to de-risk it.
The debate
What to watch next
1 · GHAVP nuclear pump testing—Sep 2026 onward
Testing resumption after NPCIL test-bed fix will show whether the pump passes validation on schedule. Delay or failure pushes revenue recognition further and raises execution risk on new tenders. Watch for management progress updates in Q2 results (mid-October).
2 · Valves margin recovery—Q2 FY-2027 results
Will valves segment margin begin recovering from single-digit, or remain stuck? Look for evidence of export clearances and sales momentum. If valves margin remains single-digit by Q2, it signals the issue is deeper than temporary geopolitical drag.
3 · H2 export and solar ramp—Q3/Q4 updates
The bull case hinges on H2 recovery: export clearances, KUSUM 2.0 launch (Q3/Q4), project finalization. Q2 and Q3 results will show materialization on schedule. If Q2 shows continued weakness or guidance holds flat, the recovery call is in jeopardy.
The verdict
Rating: HOLD (Confidence 6/10)
KSB delivered soft Q1 on revenue (3.6% vs 15–20% guidance) and profit (−18.8% YoY), blamed on geopolitical crisis, supply-chain stress, and commodity inflation in fixed-price contracts. The call shows some issues (valves, solar) are structural, not temporary. Management is defending near-term through cost control and H2 recovery hopes, but visibility is weak. Nuclear, data-centre, and infrastructure tailwinds are real and multiannual, but execution is delayed and dependent on external factors (NPCIL, government schemes, geopolitical normalization). The market has repriced the stock −22.55% from ATH; FII are exiting; the post-result move held negative. A hold is appropriate until Q2/Q3 results clarify H2 recovery pace.
KSB's long-term structural opportunity (nuclear 100GW, data-centre cooling, water infrastructure) remains intact, and the 17% revenue CAGR history supports execution capability. But the near-term margin squeeze is real, recovery timelines are external, and the stock is already −22.55% from ATH. Waiting for H2 visibility (October–November results) is prudent; entry should be timed to Q2 guidance acceleration or export/solar recovery signals, not on hope alone. The number to track from here: H2 revenue growth rate and Q3 valves margin—these will tell us whether near-term headwinds are easing or persisting.